<DOC>
	<DOCNO>NCT01842893</DOCNO>
	<brief_summary>The purpose study assess clinical effectiveness Fentanyl ETHYPHARM use relieve breakthrough pain ( BTP ) opioid-treated cancer patient .</brief_summary>
	<brief_title>Efficacy Safety Fentanyl ETHYPHARM Breakthrough Pain Opioid-treated Patients With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Inclusion criterion : 1 . Written inform consent 2 . Malignant solid tumor hematological malignancy cause cancerrelated pain 3 . Background opioid treatment stable dose least week 4 . One four episode breakthrough pain per day Main exclusion criterion : 1 . Hypersensitivity fentanyl excipients 2 . Intrathecal opioids 3 . Recent history substance abuse 4 . Recent planned therapy would alter pain 5 . Moderate severe hepatic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>fentanyl</keyword>
	<keyword>breakthrough pain</keyword>
	<keyword>opioid treated cancer patient</keyword>
</DOC>